The effect of thyroid autoimmunity on T-cell responses in early pregnancy. (August 2015)

• Record Type: Journal Article
• Authors: Turhan Iyidir, Ozlem; Konca Degertekin, Ceyla; Sonmez, Cemile; Atak Yucel, Ayşegül; Erdem, Mehmet; Akturk, Mujde; Ayvaz, Goksun
• Is Part Of: Journal of reproductive immunology. Volume 110(2015)
• Page Start: 61
• Page End: 66
• Publication Date: 2015-08
• Subjects: Thyroid autoimmunity -- Pregnancy -- T-helper -- Cytokine; Reproduction -- Immunological aspects -- Periodicals; Immunology -- Periodicals; Allergy and Immunology -- Periodicals; Reproduction -- Periodicals; Reproduction -- Immunologie -- Périodiques; Immunologie -- Périodiques; Immunology; Reproduction -- Immunological aspects; Periodicals; Electronic journals; Electronic journals; 615.766
• DOI: 10.1016/j.jri.2015.04.002
• Languages: English
• ISSNs: 0165-0378

Abstract

Highlights: Th1-, Th2-, and Th17-associated cytokines of pregnant women with TAI are evaluated. Patients were subclassified as having LT4 treatment initiated before or during the 1st trimester. Th1- and Th17-associated cytokines were higher in women with TAI in the first trimester. Cytokine levels of TAI (+) women were similar to those of the control group in the 2nd trimester. LT4 may aid successful implantation through immunomodulation in early pregnancy. Abstract: Thyroid autoimmunity (TAI) is common in women of reproductive age. There is a relationship between TAI and recurrent pregnancy loss and infertility. In pregnant patients with thyroid autoimmunity, the T helper-1 (Th1)/T helper-2 (Th2) ratio may shift to a Th1-type response and these activated T lymphocytes may lead to implantation failure. The aims of this study were to investigate the serum levels of Th1-, Th2-, and T-helper-17-(Th17)-associated cytokines in pregnant patients with TAI, and to evaluate how these cytokines change withl -thyroxin treatment during pregnancy. Twenty pregnant women with TAI diagnosed in the first trimester of pregnancy who were not onl -thyroxine treatment, 14 pregnant women with known TAI before pregnancy already been onl -thyroxine treatment, and 19 pregnant patients without TAI were included in this study. Thyroid function tests, thyroid autoantibodies, and cytokine levels were measured at the first and the second trimesters. In pregnant patients who were diagnosed with TAI in the first trimester, both serum IL-2 levels and IL-17 levels were significantly higher than those of the control group. There were no significant differences between groups for serum IL-4, IL-6, IL-23, IL-10, and IFNγ levels. In the second trimester, no significant differences were found between groups for all the cytokines measured. There are significant differences in Th1- and Th17-associated cytokine levels between patients with TAI and the control group in the first trimester. In the second trimester cytokine levels were similar among all groups. This pattern may be associated with the clinical benefits ofl -thyroxine treatment.